Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl} -3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo

Journal of Medicinal Chemistry

Volumn 55, Issue 8, 2012, Pages 3852-3866

  Li, Wei Wei ^a,b   Wang, Xiao Yan ^a,b   Zheng, Ren Lin ^a   Yan, Heng Xiu ^a   Cao, Zhi Xing ^a   Zhong, Lei ^a   Wang, Ze Rong ^a   Ji, Pan ^a   Yang, Ling Ling ^a   Wang, Li Jiao ^a   Xu, Yong ^a   Liu, Jing Jing ^a   Yang, Jiao ^a   Zhang, Chun Hui ^a   Ma, Shuang ^a   Feng, Shan ^a   Sun, Qi Zheng ^a   Wei, Yu Quan ^a   Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 [7 (3 MORPHOLINOPROPOXY)QUINAZOLIN 4 YLTHIO] [1,3,4]THIADIAZOL 2 YL] 3 1,4 TOLYLUREA; ANTILEUKEMIC AGENT; CD135 ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TUMOR REGRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; PHENYLUREA COMPOUNDS; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860310368     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300042x     Document Type: Article

References (33)

1. Lyman, S. D.; James, L.; Zappone, J.; Sleath, P. R.; Beckmann, M. P.; Bird, T. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene Oncogene 1993, 8, 815-822 (Pubitemid 23087411)
2. Rosnet, O.; Schiff, C.; Pebusque, M. J.; Marchetto, S.; Tonnelle, C.; Toiron, Y.; Birg, F.; Birnbaum, D. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells Blood 1993, 82, 1110-1119 (Pubitemid 23253983)
3. Lyman, S. D. Biology of Xt3 ligand and receptor Int. J. Hematol. 1995, 62, 63-73
4. Gilliland, D. G.; Griffin, J. D. The roles of FLT3 in hematopoiesis and leukemia Blood 2002, 100, 1532-1542 (Pubitemid 34925124)
5. Levis, M.; Small, D. FLT3 tyrosine kinase inhibitors Int. J. Hematol. 2005, 82, 100-107 (Pubitemid 41233167)
6. Cloos, J.; Goemans, B. F.; Hess, C. J. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples Leukemia 2006, 20, 1217-1220 (Pubitemid 43905824)
7. Gale, R. E.; Green, C.; Allen, C. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Blood 2008, 111, 2776-2784
8. Meshinchi, S.; Alonzo, T. A.; Stirewalt, D. L. Clinical implications of FLT3 mutations in pediatric AML Blood 2006, 108, 3654-3661 (Pubitemid 44864541)
9. Kiyoi, H.; Yanada, M.; Ozekia, K. Clinical significance of FLT3 in leukemia Int. J. Hematol. 2005, 82, 85-92 (Pubitemid 41233165)
10. Meshinchi, S.; Alonzo, T. A.; Stirewalt, D. L. Clinical implications of FLT3 mutations in pediatric AML Blood 2006, 108, 3654-366
11. Schlenk, R. F.; Dohner, K.; Krauter, J. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N. Engl. J. Med. 2008, 358, 1909-1918 (Pubitemid 351620111)
12. Giles, F. J.; Stopeck, A. T.; Sliverman, L. R.; Lancet, J. E.; Cooper, M. A.; Hannah, A. L.; Cherrington, J. M.; O'Farrell, A. M.; Yuen, H. A.; Louie, S. G.; Hong, W.; Cortes, J. E.; Verstovsek, S.; Albitar, M.; O'Brien, S. M.; Kantarjian, H. M.; Karp, J. E. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes Blood 2003, 102, 795-801 (Pubitemid 36917765)
13. O'Farrell, A. M.; Abrams, T. J.; Yuen, H. A.; Ngai, T. J.; Louie, S. G.; Yee, K. W. H.; Wong, L. M.; Hong, W.; Lee, L. B.; Town, A.; Smolich, B. D.; Manning, W. C.; Murray, L. J.; Heinrich, M. C.; Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 2003, 101, 3597-3605 (Pubitemid 36857948)
14. Menezes, D. E. L. d.; Peng, J.; Garrett, E. N.; Louie, S. G.; Lee, S. H.; Wiesmann, M.; Tang, Y.; Shephard, L.; Goldbeck, C.; Oei, Y.; Ye, H.; Aukerman, S. L.; Heise, C. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia Clin. Cancer Res. 2005, 11, 5281-5291 (Pubitemid 41003717)
15. Stone, R. M.; De Angelo, J.; Galinsky, I.; Estey, E.; Klimek, V.; Grandin, W.; Lebwohl, D.; Cohen, P.; Fox, E.; Neuberg, D.; Clark, J.; Gilliand, D. G.; Griffin, J. D. PKC 412 Flt3 inhibitor therapy in AML: results of a phase II trial Ann. Hematol. 2004, 83 (Suppl 1) S80-90
16. Smith, B. D.; Levis, M.; Beran, M.; Giles, F.; Kantarjian, H.; Berg, K.; Murphy, K. M.; Dauses, T.; Allebach, J.; Small, D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Blood 2004, 103, 3669-3676 (Pubitemid 38596280)
17. DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R. J.; Lecerf, M.; Karol, M. D.; Sheng, S.; Holford, N.; Curtin, P. T.; Druker, B. J.; Heinrich, M. C. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics Blood 2006, 108, 3674-3681 (Pubitemid 44864544)
18. Zhang, W.; Konopleva, M.; Shi, Y. X.; McQueen, T.; Harris, D.; Ling, X.; Estrov, Z.; Quintás-Cardama, A.; Small, D.; Cortes, J.; Andreeff, M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia J. Natl. Cancer Inst. 2008, 100, 184-198 (Pubitemid 351480557)
19. Shiotsu, Y.; Kiyoi, H.; Ishikawa, Y.; Tanizaki, R.; Shimizu, M.; Umehara, H.; Ishii, K.; Mori, Y.; Ozeki, K.; Minami, Y.; Abe, A.; Maeda, H.; Akiyama, T.; Kanda, Y.; Sato, Y.; Akinaga, S.; Naoe, T. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation Blood 2009, 114, 1607-1617
20. Cortes, J.; Ghirdaladze, D.; Foran, J. M.; DeVetten, M. P.; Zodelava, M.; Levis, M. J.; Padre, N. M.; James, J.; Zarrinkar, P. P.; Corringham, R. Phase 1 AML study of AC220, a potent and selective second generation FLT3 receptor tyrosine kinase inhibitor Blood 2008, 112, 767
21. Pratz, K. W.; Cortes, J.; Roboz, G. J.; Rao, N.; Arowojolu, O.; Stine, A.; Shiotsu, Y.; Shudo, A.; Akinaga, S.; Small, D.; Karp, J. E.; Levis, M. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response Blood 2009, 113, 3938-3946
22. DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R. J.; Lecerf, M.; Karol, M. D.; Sheng, S.; Holford, N.; Curtin, P. T.; Druker, B. J.; Heinrich, M. C. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics Blood 2006, 108, 3674-3681 (Pubitemid 44864544)
23. Knapper, S.; Burnett, A. K.; Littlewood, T.; Kell, W. J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M. J.; Small, D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy Blood 2006, 108, 3262-3270
24. Li, W. W.; Chen, J. J.; Zheng, R. L.; Zhang, W. Q.; Cao, Z. X.; Yang, L. L.; Qing, X. Y.; Zhou, L. X.; Yang, L.; Yu, L. D.; Chen, L. J.; Wei, Y. Q.; Yang, S. Y. Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3 ChemMedChem 2010, 5, 513-516
25. Duffel, M. W.; Ing, I. S.; Segarra, T. M.; Dixson, J. A.; Barfknecht, C. F.; Schoenwald, R. D. N- Substituted sulfonamide carbonic anhydrase inhibitors with topical effects on intraocular pressure J. Med. Chem. 1986, 29, 1488-1494 (Pubitemid 16034643)
26. Zhong, P.; Guo, M. P. Stereo-selective synthesis of (Z)-ketene selenothioacetals via hydrozirconation of alkylacetylenic selenides J. Chem. Res. Synopses 1995, 9, 370-371
27. Almajan, G. L.; Innocenti, A.; Puccetti, L.; Manole, G.; Barbuceanu, S.; Saramet, I.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols Bioorg. Med. Chem. Lett. 2005, 15, 2347-2352 (Pubitemid 40523099)
28. Kim, K. S.; Kimball, S. D.; Misra, R. N.; Rawlins, D. B.; Hunt, J. T.; Xiao, H. Y.; Lu, S.; Qian, L.; Han, W. C.; Shan, W.; Mitt, T.; Cai, Z. W.; Poss, M. A.; Zhu, H.; Sack, J. S.; Tokarski, J. S.; Chang, C. Y.; Pavletich, N.; Kamath, A.; Humphreys, W. G.; Marathe, P.; Bursuker, I.; Kellar, K. A.; Roongta, U.; Batorsky, R.; Mulheron, J. G.; Bol, D.; Fairchild, C. R.; Lee, F. Y.; Webster, K. R. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities J. Med. Chem. 2002, 45, 3905-3927 (Pubitemid 35024294)
29. Smith, N. R.; James, N. H.; Oakley, I.; Wainwright, A.; Copley, C.; Kendrew, J.; Womersley, L. M.; Jürgensmeier, J. M.; Wedge, S. R.; Barry, S. T. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts Mol. Cancer. Ther. 2007, 6, 2198-2208 (Pubitemid 47294748)
30. Brave, S. R.; Ratcliffe, K.; Wilson, Z.; James, N. H.; Ashton, S.; Wainwright, A.; Kendrew, J.; Dudley, P.; Broadbent, N.; Sproat, G.; Taylor, S.; Barnes, C.; Silva, J. C.; Farnsworth, C. L.; Hennequin, L.; Ogilvie, D. J.; Jürgensmeier, J. M.; Shibuya, M.; Wedge, S. R.; Barry, S. T. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family Mol. Cancer. Ther. 2011, 10, 861-873
31. Pandey, A.; Volkots, D. L.; Seroogy, J. M.; Rose, J. W.; Yu, J. C.; Lambing, J. L.; Hutchaleelaha, A.; Hollenbach, S. J.; Abe, K.; Giese, N. A.; Scarborough, R. M. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family J. Med. Chem. 2002, 45, 3772-3793 (Pubitemid 34856116)
32. Mortlock, A. A.; Foote, K. M.; Heron, N. M.; Jung, F. H.; Pasquet, G.; Lohmann, J. J. M.; Warin, N.; Renaud, F.; Savi, C. D.; Roberts, N. J.; Johnson, T.; Dousson, C. B.; Hill, G. B.; Perkins, D.; Hatter, G.; Wilkinson, R. W.; Wedge, S. R.; Heaton, S. P.; Odedra, R.; Keen, N. J.; Crafter, C.; Brown, E.; Thompson, K.; Brightwell, S.; Khatri, L.; Brady, M. C.; Kearney, S.; McKillop, D.; Rhead, S.; Parry, T.; Green, S. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase J. Med. Chem. 2007, 50, 2213-2224 (Pubitemid 46683074)
33. Bemis, G. W.; Harbeson, S. L.; Ledeboer, M. Inhibitors of JAK protein kinase. US 20040038992 A120040226.